Pfizer expected to report lower Q2 results than estimates, facing challenges, uncertain macroeconomic environment

From Nasdaq: 2024-07-28 21:01:16

Pfizer is set to report Q2 2024 results with expected revenue of $12.95 billion and earnings of $0.44 per share, lower than estimates. Stock performance has been inconsistent, underperforming the S&P. The uncertain macroeconomic environment could impact future performance. Q1 2024 saw a revenue decline of 19% y-o-y. Pfizer expects 2024 revenue between $58.5B and $61.5B.

While Pfizer’s stock performance has been shaky, its Q2 results are eagerly anticipated, with revenue and earnings expected to fall short of estimates. The company has faced challenges in the past year, such as a decline in Covid-19 product sales. Despite strong sales in Vyndaqel and Abrysvo, the company’s adjusted net margin dropped significantly.

Pfizer’s stock is currently fully priced, trading at 13x forward expected earnings. The company’s valuation multiple has fluctuated due to pandemic-related growth. Looking ahead, Pfizer anticipates sales growth in 2024 but may struggle to meet street estimates. Investors should closely monitor how Pfizer’s peers are performing in the market, especially against the backdrop of a volatile macroeconomic environment.

Investors can track Pfizer’s performance against the S&P 500 and other benchmarks with Trefis’ High Quality Portfolio. Despite past underperformance, Pfizer remains a key player in the healthcare sector. As the company navigates changing market conditions, monitoring key financial metrics will be crucial for investors seeking stable returns.



Read more at Nasdaq: Will Pfizer Stock Post A Downbeat Q2?